UGX-06

UGX-06 is an investigational gene therapy developed by Suzhou Xingming Youjian Biotechnology. It utilizes an adeno-associated virus (AAV) vector to deliver genetic material targeting opsin receptors, aiming to modulate their activity. The primary therapeutic focus of UGX-06 is on congenital eye diseases, with a particular emphasis on retinitis pigmentosa, a group of inherited retinal disorders that cause progressive vision loss. The drug acts as a modulator of opsin receptors and is designed to address underlying genetic defects in affected patients[1][4]. As of the latest updates, development has reached Phase 1 clinical trials but has been suspended[1][4].